biostudies-literatureUnknown13(9)Suh JWObjectives: This study aimed to compare clinical characteristics, antimicrobial susceptibility, and 28-day mortality between patients with Acinetobacter baumannii bacteremia (ABB) and non-baumannii Acinetobacter bacteremia (NBAB) after rapid matrix-assisted laser desorption ionization time-of-flight (MALDI-TOF) mass spectrometry (MS) species identification. Methods: We retrospectively reviewed the clinical data of adult ABB and NBAB patients over >7 years. Multivariate logistic regression was used to identify the risk factors for 28-day mortality. Results: Of 273 episodes of Acinetobacter species bacteremia, 224 (82.1%) were ABB and 49 (17.9%) were NBAB. NBA isolates were predominantly A. nosocomialis (49%), with smaller proportions of A. bereziniae, A. junii, A. ursingii, and others. The primary sites of infection in NBAB cases were the intra-abdomen, urinary tract, intravascular catheters, and lungs. While only 4.0% of A. baumannii isolates were susceptible to carbapenem, 87.8% of non-baumannii Acinetobacter isolates were susceptible. Multivariate analysis revealed that low carbapenem resistance was independently associated with NBAB. Additionally, a higher Pitt bacteremia score, septic shock, continuous renal replacement therapy, inappropriate empirical antibiotic therapy, and thrombocytopenia were independent risk factors for the 28-day mortality in patients with ABB. Conclusions: Although less common than ABB, NBAB cases are increasing and exhibit lower carbapenem resistance. Rapid MALDI-TOF MS identification enables timely and appropriate antibiotic treatment. The key factors driving the 28-day mortality include illness severity, septic shock, renal replacement therapy, inappropriate antibiotics, and thrombocytopenia, highlighting the need for early risk assessments and tailored management. Ongoing surveillance and species-specific strategies are essential for combating resistant Acinetobacter infections.Biomedicines2304https://www.ebi.ac.uk/biostudies/studies/S-EPMC12467366biostudies-literatureClinical Implications of Bacteremia Caused by Non-baumannii Acinetobacter Compared with Those of Acinetobacter baumannii Bacteremia.PMC12467366Suh JWKim KJKim SBHong JYHong DJfalseClinical Implications of Bacteremia Caused by Non-baumannii Acinetobacter Compared with Those of Acinetobacter baumannii Bacteremia.Objectives: This study aimed to compare clinical characteristics, antimicrobial susceptibility, and 28-day mortality between patients with Acinetobacter baumannii bacteremia (ABB) and non-baumannii Acinetobacter bacteremia (NBAB) after rapid matrix-assisted laser desorption ionization time-of-flight (MALDI-TOF) mass spectrometry (MS) species identification. Methods: We retrospectively reviewed the clinical data of adult ABB and NBAB patients over >7 years. Multivariate logistic regression was used to identify the risk factors for 28-day mortality. Results: Of 273 episodes of Acinetobacter species bacteremia, 224 (82.1%) were ABB and 49 (17.9%) were NBAB. NBA isolates were predominantly A. nosocomialis (49%), with smaller proportions of A. bereziniae, A. junii, A. ursingii, and others. The primary sites of infection in NBAB cases were the intra-abdomen, urinary tract, intravascular catheters, and lungs. While only 4.0% of A. baumannii isolates were susceptible to carbapenem, 87.8% of non-baumannii Acinetobacter isolates were susceptible. Multivariate analysis revealed that low carbapenem resistance was independently associated with NBAB. Additionally, a higher Pitt bacteremia score, septic shock, continuous renal replacement therapy, inappropriate empirical antibiotic therapy, and thrombocytopenia were independent risk factors for the 28-day mortality in patients with ABB. Conclusions: Although less common than ABB, NBAB cases are increasing and exhibit lower carbapenem resistance. Rapid MALDI-TOF MS identification enables timely and appropriate antibiotic treatment. The key factors driving the 28-day mortality include illness severity, septic shock, renal replacement therapy, inappropriate antibiotics, and thrombocytopenia, highlighting the need for early risk assessments and tailored management. Ongoing surveillance and species-specific strategies are essential for combating resistant Acinetobacter infections.2025-01-01T00:00:00Z2025 Sep2026-05-02T03:15:10.695Z2026-05-02T03:09:22.651ZS-EPMC124673664100786410.3390/biomedicines13092304